BeOne Medicines (ONC) CEO receives new performance share awards

Rhea-AI Filing Summary

OYLER JOHN reported acquisition or exercise transactions in this Form 4 filing.

BeOne Medicines Ltd. reported that Chief Executive Officer John Oyler received two equity awards of Ordinary Shares as compensation. On March 6, 2026, he was granted 326,976 shares underlying earned performance share units that vest in 2027, and an additional 117,936 shares underlying earned performance share units that vest in 2028, in each case at no cash cost to him and subject to his continued service, with potential accelerated vesting upon a change of control or certain termination events. Following these awards, Oyler directly holds 5,609,275 Ordinary Shares. The filing also notes several indirect holdings in trusts and an LLC where he disclaims beneficial ownership, plus shares held for his benefit in a Roth IRA account.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

OYLER JOHN

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/06/2026		A		326,976(1)	A	$0	5,491,339	D
Ordinary Shares	03/06/2026		A		117,936(2)	A	$0	5,609,275	D
Ordinary Shares								481,533	I	See Footnote(3)
Ordinary Shares								7,699,158	I	See Footnote(4)
Ordinary Shares								28,204,115	I	See Footnote(5)
Ordinary Shares								9,545,000	I	See Footnote(6)
Ordinary Shares								102,188	I	See Footnote(7)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2027, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.

2. Represents the total number of ordinary shares underlying the performance share units earned by Reporting Person. The earned performance share units will vest in 2028, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Unvested shares are subject to accelerated vesting upon change of control or certain termination events.

3. These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.

4. These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

5. These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

6. These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

7. These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BeOne Medicines (ONC) CEO John Oyler report in this Form 4?

John Oyler reported receiving equity awards of Ordinary Shares. On March 6, 2026, he was granted performance-share-based Ordinary Shares at no cash cost, increasing his direct holdings while documenting additional indirect holdings through various trusts and an IRA account.

How many BeOne Medicines Ordinary Shares were granted to the CEO in this filing?

The CEO was granted 326,976 and 117,936 Ordinary Shares. These grants represent earned performance share units that will settle in shares, substantially increasing his direct equity position as part of his compensation rather than through open-market purchases.

When do John Oyler’s new BeOne Medicines performance share units vest?

The earned performance share units vest in 2027 and 2028. One tranche linked to 326,976 shares is scheduled to vest in 2027, and another linked to 117,936 shares in 2028, subject to Oyler’s continued service and certain accelerated vesting conditions.

What is John Oyler’s direct BeOne Medicines share ownership after these grants?

After the grants, Oyler directly holds 5,609,275 Ordinary Shares. This figure reflects his updated direct ownership position following the March 6, 2026 equity awards described as earned performance share units with future vesting dates.

Are there indirect BeOne Medicines holdings associated with John Oyler?

Yes, several indirect holdings are reported in trusts and an LLC. The filing notes interests held by the P&O Trust, a grantor retained annuity trust, Oyler Investment LLC, and The John Oyler Legacy Trust, where Oyler disclaims beneficial ownership, plus shares held for him in a Roth IRA.

Do these BeOne Medicines Form 4 transactions involve open-market buying or selling?

No, the reported transactions are compensation-related grants. Both transactions use code “A” for grant or award acquisitions of performance share units, with a reported price of $0.0000 per share, and do not reflect open-market purchases or sales.